<DOC>
	<DOC>NCT02673710</DOC>
	<brief_summary>The purpose of this study is to explore the relationship between sarcopenia, as defined by computed tomography, treatment related outcomes and other body composition related parameters in a patient population receiving bevacizumab beyond progression.</brief_summary>
	<brief_title>A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Survivors Treated With Chemotherapy Combined With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Sarcopenia</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt;= 18 years Participants treated in first line with bevacizumab for whom it is decided to continue the treatment with Bevacizumab beyond first progression Participants with Metastatic Colorectal Cancer (mCRC) that comply with the beyond Progressive Disease (PD1) reimbursement criteria Women of childbearing potential have to use effective contraception during (and up to 6 months after) treatment. Availability of specific retrospective data at diagnosis and during 1st line treatment Participants who received the 1st line or are still participating in any other clinical trial or study with the exception of participation in registry trials Dementia or another mental condition making it impossible to fill out questionnaires</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>